

Supporting Information

One-Step Heck Reaction Generates Non-Immunosuppressive FK506 Analogs for Pharmacological BMP Activation

Yuefan Wang^{1,2}, Brandon Peiffer^{1,2}, Qi Su³, Jun O Liu^{1,2}

¹Department of Pharmacology, Johns Hopkins School of Medicine, Baltimore, MD 21205, USA.

²The SJ Yan and HJ Mao Laboratory of Chemical Biology, Johns Hopkins School of Medicine, Baltimore, MD 21205, USA.

³Department of Chemistry, Johns Hopkins University, 3400N. Charles St., Baltimore, MD 21218, USA

Email: joliu@jhu.edu

Table of Contents

E x p e r i m e n t a l Methods.....	3
E x p e r i m e n t a l Data.....	5
Optimization of the Heck reaction conditions (Table S1).....	5
General procedure for the Heck reaction.....	6
Statistical data for BMP reporter EC ₅₀ analysis (Table S2).....	9
Figure S1. Proposed workflow for identification of clinic-ready FK506 analogs for pharmacological BMP activation.....	10
S p e c t r o s c o p i c Data.....	11

EXPERIMENTAL METHODS AND EQUIPMENT

Normal phase disposable flash columns RediSep®Rf for flash chromatography were purchased from Teledyne Isco, Inc. Solvent was used extra dry over molecular sieve, stabilized, AcroSeal®. Yields refer to chromatographically homogeneous materials. Reactions were monitored by mass spectrometry provided by Agilent 6120 Quadrupole LC/MS. PLC Silica gel 60 F₂₅₄, 1mm supplied by EMD Millipore using UV light as visualizing agent.

¹H-NMR was recorded on Bruker Avance III 500 MHz NMR spectrometer. TMS was used as internal standard for ¹H-NMR (0 ppm). High-resolution mass spectra (HRMS) were recorded on Waters Synapt G2-Si mass spectrometer using ESI (electrospray ionization). FK-506 (Tacrolimus) was purchased from Biotang Inc. Zhan-1b catalyst, palladium acetate and tris(o-tolyl)phosphine were purchased from Aldrich.

Cell Culture and Transfections

Jurkat (E6.1, ATCC) cells were cultured in RPMI (buffered to pH=7.5) with 10% FBS and 1.5% PennStrep. Jurkat cells (1 x 10⁶) were transfected with 10 µg of BRE-Luciferase (kindly provided by Martine Roussel & Peter ten Dijke) or NFAT-Luciferase cDNA (Promega) by electroporation (BioRad, square-wave, 250V, 950µF) in 400 µL serum/antibiotic free RPMI with 0.5% DMSO. Thirty minutes after transfection, cells were transferred to complete RPMI and rested overnight. Before plating, cells were re-suspended in fresh media and diluted to 0.5x10⁶ cells/mL. HUVEC cells were cultured in Lonza Endothelial cell Growth Medium (EGM-2) and used between passages 3 and 7.

All cells were grown and assayed at pH=7.5 (extracellular)*, 37°C, with 5% added CO₂.

*In the pH range between 6.8 and 7.4, lymphocytes maintain a constant internal pH of 7.17 +/- 0.06 pH unit.

Cell Viability Assays

HUVEC cells were plated at 1000 cells/well in 180µL growth media before addition of 20µL of 10X drug/protein stock. After 72-hour treatment, 22uL of a resazurin sodium salt solution (0.1mg/mL stock in water) was added to each well and allowed to incubate at 37°C. The metabolic conversion of resazurin dye was monitored by absorbance at 570nm after 6 hours. After background subtraction (media only + dye), absorbance values were left as arbitrary absorbance units or normalized to those obtained by DMSO.

BMP and NFAT Pathway Reporters

Jurkat cells used for each experiment were transfected at the same time and cultured together overnight until plating and treatment the following day.

Jurkat T cells transfected with BRE-Luc were split into a 96-well plate (80uL/well of 0.5×10^6 cells/mL) and treated with previously stated compounds (20μL of 5X stock in RPMI, 0.5% DMSO) for 18 hours. Cells were lysed and measured for luminescence as previously reported (Peiffer et al., 2018). Luminescence values were background subtracted (lysis buffer + substrate) and normalized to DMSO control values.

Jurkat T cells transfected with NFAT-Luc were split into a 96-well plate (80uL/well of 0.5×10^6 cells/mL) and treated with indicated compounds (20μL of 5X stock in RPMI, 0.5% DMSO) 30 min before activation with PMA/Ionomycin (40nM/1μM). After 6 hours, wells were lysed and measured for luminescence as previously stated (B. Peiffer et al., 2018). FK506 and served as positive control while DMSO and non-activated wells gave negative and background control values, respectively.

Western Blot

Jurkat cells were plated at 1.5×10^6 cells/well in a 12 well plate before addition of compounds or vehicle control (DMSO). After 2 hours, cells were collected, centrifuged (300g, 5min), and washed with PBS before lysis with 75μL RIPA buffer (including protease/phosphatase inhibitor cocktail, Cell Signaling Technologies). Protein levels were normalized with DC protein assay (BioRad), and boiled with 4X laemmli buffer. 25ug of each cell lysate was run on a 10% PAGE gel before transfer to a nitrocellulose (0.2μm) membrane. Blots were blocked with milk and stained overnight at 4°C with primary antibodies for phosphor-SMAD1/5 (1:500, Cell Signaling Technologies) and HSP90 (Loading control, 1:1000, Santa Cruz). After washing, secondary antibodies (HRP conjugate, 1:7500, Cell Signaling Technologies) were incubated for 2 hours before washing and addition of chemi-luminescent substrate. Developed blots were imaged on a SynGene gel imager.

EC₅₀ Calculations


Calculations were performed using GraphPad Prism 6. Curves were fit using non-linear, log(agonist) vs. response (three parameters). 95% confidence intervals of EC50 values are reported below.

EXPERIMENTAL DATA

Optimization of Heck reaction conditions:

To a mixture of FK-506 (0.0500 mmol, 40 mg, 1.0 equiv), Pd(OAc)₂ (0.00500 mmol, 1.1 mg, 0.10 equiv), P(*o*-tol)₃ (0.0100 mmol, 3.0 mg, 0.20 equiv), base and additives in flame-dried 10 mL-Schlenk tube, dry DMF (1.0 mL) was added under Ar balloon protection, and the mixture was stirred at specific temperature. The reactions were monitored by mass spectrometry.


Table S1. Survey of best reaction condition for Heck reaction



Entry	base	additives	temperature	time / h	Yield (%) ^b
1	NaHCO ₃	ⁿ Bu ₄ NBr	100 °C	24	N. D.
2	NaHCO ₃	none	100 °C	24	decomposed
3	K ₂ CO ₃	ⁿ Bu ₄ NBr, H ₂ O	50 °C	2	decomposed
4	NaHCO ₃	ⁿ Bu ₄ NCl	100 °C	24	decomposed
5	2,6-lutidine	none	100 °C	24	low conversion
6	Et ₃ N	none	100 °C	24	66


General procedure for the Heck reaction

To a mixture of FK-506 (0.0500 mmol, 40 mg, 1.0 equiv), aryl halides (2.0 equiv) and Pd(OAc)₂ (0.00500 mmol, 1.1 mg, 0.10 equiv) and P(*o*-tol)₃ (0.0100 mmol, 3.0 mg, 0.20 equiv) in flame-dried 10 mL-Schlenk tube, dry DMF (1.0 mL) and Et₃N (0.10 mL) dried over K₂CO₃ was added under Ar balloon protection, and the mixture was stirred at 100 °C. The reactions were monitored by mass spectrometry. When the reaction was finished, the reaction mixture cooled to room temperature, and was purified by flash column with gradient solvent (dichloromethane and methanol) to give the corresponding product. If necessary, PLC was used as further purification to separate epimers.




1b: ¹H-NMR (500MHz, CDCl₃) 8.51 (br s, 2H), 7.18 (br s, 2H), 6.40-6.32


(m, 2H), 5.33 and 5.18 (rotamers, d, $J = 1.05$, 1H), 5.11-5.05 (m, 2H), 4.99 and 4.65 (rotamers, d, $J = 4.55$, 1H), 4.71 and 4.24 (rotamers, s, 1H), 4.43 and 3.72 (rotamers, d, $J = 12.5$, 1H), 3.94-3.84 (m, 1H), 3.72-3.61 (m, 2H), 3.44-3.35 (m, 9H), 3.34-3.29 (m, 3H), 3.06-2.96 (m, 2H), 2.84-2.61 (m, 3H), 2.33-2.25 (m, 2H), 2.21-1.96 (m, 7H), 1.95-1.85 (m, 2H), 1.72-1.44 (m, 18H), 1.03-0.81 (m, 11H); HRMS (ESI): m/z calcd for $C_{49}H_{73}N_2O_{12}$ $[M+H]^+$: 881.5164, found 881.5164.




2b: 1H -NMR (500MHz, $CDCl_3$) 7.93 (br s, 1H), 6.60 (br s, 1H), 6.38 (br s, 1H), 6.32-6.18 (m, 2H), 5.33 and 5.18 (rotamers, d, $J = 1.05$, 1H), 5.12-5.02 (m, 2H), 4.94 and 4.64 (rotamers, d, $J = 4.50$, 1H), 4.69 (br s, 2H), 4.43 and 3.72 (rotamers, d, $J = 14.6$, 1H), 3.95-3.84 (m, 1H), 3.74-3.66 (m, 1H), 3.60-3.53 (m, 1H), 3.46-3.23 (m, 12H), 3.04-2.99 (m, 2H), 2.82-2.62 (m, 2H), 2.40-2.24 (m, 4H), 2.17-1.99 (m, 8H), 1.85-1.71 (m, 3H), 1.71-1.31 (m, 16H), 1.03-0.82 (m, 11H); HRMS (ESI): m/z calcd for $C_{49}H_{74}N_3O_{12}$ $[M+H]^+$: 896.5272, found 896.5261.




3b: 1H -NMR (500MHz, $CDCl_3$) 8.04 (s, 1H), 7.95 (s, 1H), 7.05-6.98 (m, 1H), 6.40-6.35 (m, 1H), 6.20-6.10 (m, 1H), 5.34 and 5.20 (rotamers, s, 1H), 5.12-5.04 (m, 2H), 4.94 and 4.64 (rotamers, d, $J = 4.40$, 1H), 4.43 and 3.72 (rotamers, d, $J = 13.4$, 1H), 4.00-3.90 (m, 1H), 3.72 (br s, 2H), 3.61-3.47 (m, 2H), 3.44-3.35 (m, 9H), 3.33-3.28 (m, 3H), 3.04-2.98 (m, 2H), 2.83-2.62 (m, 3H), 2.42-2.07 (m, 8H), 1.98-1.86 (m, 3H), 1.75-1.43 (m, 19H), 0.99-0.82 (m, 11H); HRMS (ESI): m/z calcd for $C_{49}H_{74}N_3O_{12}$ $[M+H]^+$: 896.5272, found 896.5262.




4b: 1H -NMR (500MHz, $CDCl_3$) 8.40 (s, 1H), 8.31 (d, $J = 4.6$, 1H), 6.52-6.41 (m, 2H), 5.33 and 5.18 (rotamers, s, 1H), 5.12-5.02 (m, 2H), 4.99 and 4.65 (rotamers, d, $J = 4.40$, 1H), 4.72 and 4.24 (rotamers, s, 1H), 4.43 and 3.70 (rotamers, d, $J = 14.6$, 1H), 3.94-3.85 (m, 1H), 3.67-3.52 (m, 2H), 3.43-3.35 (m, 9H), 3.34-3.28 (m, 3H), 3.05-2.98 (m, 2H), 2.76-2.62 (m, 3H), 2.49-2.25 (m, 4H), 2.21-1.96 (m, 7H), 1.94-1.69 (m, 5H), 1.68-1.61 (m, 7H), 1.51-1.36 (m, 7H), 1.04-0.85 (m, 11H); HRMS (ESI): m/z calcd for $C_{49}H_{72}N_2O_{12}F$ $[M+H]^+$: 899.5069, found 899.5060.




5b: 1H -NMR (500MHz, $CDCl_3$) 8.82 (d, $J = 4.55$, 1H), 8.10-8.05 (m, 2H), 7.70 (t, $J = 7.42$, 1H), 7.55 (t, $J = 7.52$, 1H), 7.36 (dd, $J = 9.2$, 4.55, 1H), 7.10 (d, $J = 15.6$, 1H), 6.36 (dt, $J = 15.4$, 7.53, 1H), 5.34 and 5.20 (rotamers, s, 1H), 5.15-5.00 (m, 2H), 4.95 and 4.65 (rotamers, d, $J = 4.85$, 1H), 4.74 and 4.27 (rotamers, s, 1H), 4.43 and 3.72 (rotamers, d, $J = 13.5$, 1H), 4.14-3.79 (m, 2H), 3.73-3.65 (m, 1H), 3.60-3.51 (m, 2H), 3.44-3.35 (m, 9H), 3.34-3.29 (m, 3H), 3.04-2.98 (m, 2H), 2.88-2.73 (m, 2H), 2.57-2.44 (m, 1H), 2.36-2.07 (m, 6H), 2.05-1.93 (m, 4H), 1.87-1.66 (m, 9H), 1.61-1.33 (m, 8H), 1.03-0.78 (m, 11H); HRMS (ESI): m/z calcd for $C_{53}H_{75}N_2O_{12}$ $[M+H]^+$: 931.5320, found 931.5322.




6b: $^1\text{H-NMR}$ (500MHz, CDCl_3) 8.89-8.86 (m, 1H), 7.85-7.81 (m, 1H), 7.53-7.36 (m, 2H), 7.06-6.99 (m, 1H), 6.45-6.32 (m, 1H), 5.78-5.67 and 5.40-5.34 (rotamers, m, 1H), 5.19-4.98 (m, 2H), 4.94 and 4.65 (rotamers, d, $J = 5.00$, 1H), 4.43 and 3.72 (rotamers, d, $J = 13.9$, 1H), 4.15-3.83 (m, 2H), 3.75-3.50 (m, 3H), 3.44-3.35 (m, 9H), 3.34-3.30 (m, 3H), 3.08-2.95 (m, 2H), 2.86-2.67 (m, 2H), 2.58-2.43 (m, 1H), 2.36-1.98 (m, 8H), 1.89-1.40 (m, 20H), 1.06-0.79 (m, 11H); HRMS (ESI): m/z calcd for $\text{C}_{53}\text{H}_{73}\text{N}_2\text{O}_{12}\text{F}_2$ $[\text{M}+\text{H}]^+$: 967.5132, found 967.5135.




7b: $^1\text{H-NMR}$ (500MHz, CDCl_3) 8.79 (s, 1H), 8.14-8.06 (m, 1H), 7.66 (d, $J = 9.50$, 1H), 7.52-7.35 (m, 2H), 6.97 (d, $J = 14.4$, 1H), 6.41-6.31 (m, 1H), 5.34 and 5.20 (rotamers, s, 1H), 5.15-4.98 (m, 2H), 4.95 and 4.66 (rotamers, d, $J = 4.85$, 1H), 4.72 and 4.27 (rotamers, s, 1H), 4.43 and 3.70 (rotamers, d, $J = 13.2$, 1H), 4.14-3.85 (m, 2H), 3.74-3.50 (m, 3H), 3.47-3.27 (m, 12H), 3.15-3.10 (m, 2H), 2.87-2.64 (m, 3H), 2.59-2.43 (m, 1H), 2.38-2.19 (m, 3H), 2.04-1.73 (m, 6H), 1.70-1.46 (m, 17H), 1.10-0.85 (m, 11H); HRMS (ESI): m/z calcd for $\text{C}_{53}\text{H}_{74}\text{N}_2\text{O}_{12}\text{F}$ $[\text{M}+\text{H}]^+$: 949.5226, found 949.5234.



8b: $^1\text{H-NMR}$ (500MHz, CDCl_3) 7.17-7.13 (m, 2H), 6.54 (d, $J = 8.30$, 2H), 6.29 (d, $J = 15.0$, 1H), 5.90-5.82 (m, 1H), 5.32 and 5.20 (rotamers, s, 1H), 5.14-5.03 (m, 2H), 5.01 and 4.62 (rotamers, d, $J = 4.10$, 1H), 4.80 and 4.27 (rotamers, s, 1H), 4.43 and 3.73 (rotamers, d, $J = 15.0$, 1H), 3.97-3.86 (m, 2H), 3.69-3.64 (m, 1H), 3.59-3.55 (m, 1H), 3.42-3.35 (m, 10H), 3.34-3.29 (m, 3H), 3.04-2.98 (m, 2H), 2.83 (s, 3H), 2.75-2.54 (m, 3H), 2.35-2.24 (m, 3H), 2.16-1.97 (m, 6H), 1.84-1.70 (m, 4H), 1.68-1.59 (m, 11H), 1.50-1.39 (m, 4H), 1.03-0.85 (m, 11H); HRMS (ESI): m/z calcd for $\text{C}_{51}\text{H}_{77}\text{N}_2\text{O}_{12}$ $[\text{M}+\text{H}]^+$: 909.5477, found 909.5473.




9b: $^1\text{H-NMR}$ (500MHz, CDCl_3) 7.13-7.09 (m, 2H), 6.61 (d, $J = 8.15$, 2H), 6.28 (d, $J = 15.7$, 1H), 5.92-5.84 (m, 1H), 5.32 and 5.19 (rotamers, s, 1H), 5.10-5.03 (m, 2H), 4.93 and 4.62 (rotamers, d, $J = 5.05$, 1H), 4.80 and 4.27 (rotamers, s, 1H), 4.43 and 3.74 (rotamers, d, $J = 14.5$, 1H), 3.97-3.89 (m, 1H), 3.69-3.64 (m, 1H), 3.61-3.52 (m, 2H), 3.42-3.37 (m, 9H), 3.32-3.28 (m, 3H), 3.03-2.98 (m, 2H), 2.75-2.63 (m, 2H), 2.33-2.25 (m, 3H), 2.20-2.03 (m, 6H), 1.83-1.72 (m, 3H), 1.66-1.48 (m, 19H), 1.00-0.86 (m, 11H); HRMS (ESI): m/z calcd for $\text{C}_{50}\text{H}_{75}\text{N}_2\text{O}_{12}$ $[\text{M}+\text{H}]^+$: 895.5320, found 895.5320.



10b: $^1\text{H-NMR}$ (500MHz, CDCl_3) 7.07 (t, $J = 7.75$, 1H), 6.72-6.69 (m, 1H), 6.64 (s, 1H), 6.54 (d, $J = 7.80$, 1H), 6.30 (d, $J = 15.7$, 1H), 6.08-6.00 (m, 1H), 5.32 and 5.20 (rotamers, s, 1H), 5.12-5.04 (m, 2H), 4.94 and 4.64 (rotamers, s, 1H), 4.75 and 4.26 (rotamers, s, 1H), 4.43 and 3.69 (rotamers, d, $J = 13.5$, 1H), 3.98-3.89 (m, 1H), 3.72-3.57 (m, 3H), 3.47-

3.36 (m, 9H), 3.34-3.27 (m, 3H), 3.06-2.97 (m, 2H), 2.69-2.56 (m, 2H), 2.36-2.25 (m, 3H), 2.19-1.97 (m, 6H), 1.82-1.71 (m, 3H), 1.69-1.47 (m, 19H), 1.03-0.85 (m, 11H); HRMS (ESI): m/z calcd for $C_{50}H_{75}N_2O_{12}$ $[M+H]^+$: 895.5320, found 895.5320.



11b: 1H -NMR (500MHz, $CDCl_3$) 7.15 (t, $J = 7.50$, 1H), 7.04(t, $J = 7.65$, 1H), 6.75-6.69 (m, 1H), 6.65 (d, $J = 7.95$, 1H), 6.42 (d, $J = 15.6$, 1H), 5.99-5.90 (m, 1H), 5.33 and 5.20 (rotamers, s, 1H), 5.14-5.04 (m, 2H), 4.95 and 4.62 (rotamers, d, $J = 4.40$, 1H), 4.73 and 4.31 (rotamers, s, 1H), 4.43 and 3.72 (rotamers, d, $J = 13.6$, 1H), 3.97-3.83 (m, 2H), 3.76-3.64 (m, 2H), 3.59-3.55 (m, 1H), 3.41-3.37 (m, 9H), 3.32-3.27 (m, 3H), 3.05-2.96 (m, 2H), 2.70-2.60 (m, 2H), 2.37-2.25 (m, 3H), 2.15-1.98 (m, 6H), 1.93-1.72 (m, 6H), 1.70-1.61 (m, 9H), 1.50-1.35 (m, 6H), 1.03-0.85

(m, 11H); HRMS (ESI): m/z calcd for $C_{50}H_{75}N_2O_{12}$ $[M+H]^+$: 895.5320, found 895.5316.

Table S2. EC_{50} values for BMP pathway reporter activation using top performing analogs.

Compound	EC_{50} (nM)
1	7.247 to 21.10

2	19.87 to 46.96
3	16.07 to 34.08
FK506	26.10 to 45.47







Figure S1. Proposed workflow for identification of clinic-ready FK506 analogs for pharmacological BMP activation. **(1)** A rationally designed FK506 analog library is screened using a high-throughput compatible, three-assay system. **(2)** Top performing candidates are then validated *in vitro* through EC₅₀ analysis in the BMP-reporter assay. **(3)** Validated compounds are moved into pre-clinical animal studies to determine inter-analog differences in ADME (absorption, distribution, metabolism, excretion) and *in vivo* toxicity profiles.


1b: ¹H-NMR





2b: ¹H-NMR




4b: ¹H-NMR





5b: ¹H-NMR



9b: ¹H-NMR



7b: ¹H-NMR



8b: ¹H-NMR





Current Data Parameters
 NAME 2018-05-15-7-FK-6F-vq-do
 EXPNO 1
 PROCNO 1


F2 - Acquisition Parameters

Date_ 20180515
 Time 18.57 h
 INSTRUM spect
 PROBHD zgpg30
 PULPROG zgpg30
 TD 65536
 SOLVENT CDCl3
 NS 128
 DS 0
 SWH 10302.198 Hz
 FIDRES 0.314398 Hz
 RG 3.180000 sec
 ACQ 223
 DW 48.533 usec
 DE 6.50 usec
 TE 296.5 K
 D1 1.0000000 sec
 D11 1.0000000 sec
 SFO1 499.803085 MHz
 NUC1 1H
 P1 11.49 usec
 PL1 14.0000000 W

F2 - Processing parameters
 SI 65536
 SF 499.8000100 MHz
 RG 3.180000 sec
 SSF 0
 LB 0.30 Hz
 GB 0
 PC 1.00





1:



1.



11b: ¹H-NMR





Current Data Parameters
 NAME 2018-10-25-11-FK-2-anil.
 EXPNO 1
 PROCNO 1

F2 - Acquisition Parameters
 Date_ 20181025
 Time 17.58 h
 INSTRUM spect
 PULPROG zgpg30
 PULPRG zgpg30
 TD 65536
 SOLVENT CDCl3
 NS 128
 DS 0
 SWH 10302.198 Hz
 AQ 0.36459 Hz
 RG 3.160609 sec
 DW 48.533 usec
 DE 6.50 usec
 TE 296.5 K
 D1 1.00000000 sec
 D10 1.00000000 sec
 SFO 499.8030865 MHz
 NUC1 1H
 P1 11.53 usec
 PLW1 14.00000000 W

F2 - Processing parameters
 SI 65536
 SF 499.8000006 MHz
 WDW EM
 SSB 0
 LB 0.30 Hz
 GB 0
 PC 1.00

